BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25557587)

  • 1. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
    Jo SJ; Shin H; Jo S; Kwon O; Myung SK
    Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
    Lian S; Zhang X; Zhang Y; Zhao Q
    Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
    Pandy JGP; Franco PIG; Li RK
    Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
    Chen M; Zhang L; Wang Q; Shen J
    PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
    Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
    Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
    von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
    Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
    Kao YS; Lo CH; Tu YK; Hung CH
    Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
    Toyama T; Yoshimura A; Hayashi T; Kobayashi N; Saito K; Tsuneizumi M; Sawaki M; Hattori M; Nakada T; Yokota I; Iwata H
    Breast Cancer; 2018 Nov; 25(6):729-735. PubMed ID: 29948956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.
    Zhou Y; Peng L; Li Y; Chen L
    Biomed Rep; 2013 Nov; 1(6):873-878. PubMed ID: 24649045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Liu Y; May BH; Zhang AL; Guo X; Lu C; Xue CC; Zhang H
    Integr Cancer Ther; 2019; 18():1534735418817833. PubMed ID: 30526124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
    Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
    Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.
    Macedo LT; Lima JP; dos Santos LV; Sasse AD
    Support Care Cancer; 2014 Jun; 22(6):1585-93. PubMed ID: 24463616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Ilyas S; Wasif K; Saif MW
    Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical non-occlusive polymers in hand-foot syndrome.
    Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
    G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
    Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
    J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.